Compile Data Set for Download or QSAR
Report error Found 16 Enz. Inhib. hit(s) with all data for entry = 608
TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281728((+)-3-(4-Chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4...)
Affinity DataEC50:  22nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281729((+)-3-(4-Chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4...)
Affinity DataEC50:  89nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281730(US10023528, Example 4 | US10023528, Example 3 | US...)
Affinity DataEC50:  37nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281730(US10023528, Example 4 | US10023528, Example 3 | US...)
Affinity DataEC50:  110nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281732(US10023528, Example 5 | US10023528, Example 6 | US...)
Affinity DataEC50:  5.20nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281732(US10023528, Example 5 | US10023528, Example 6 | US...)
Affinity DataEC50:  56nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281734(US10023528, Example 10 | US10259776, Example 10)
Affinity DataEC50:  10nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281735(US10023528, Example 12 | US10259776, Example 12)
Affinity DataEC50:  17nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281736(US10023528, Example 13 | US10259776, Example 13)
Affinity DataEC50:  14nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281737(US10023528, Example 14 | US10259776, Example 14)
Affinity DataEC50:  8.40nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281738((+)-3-(4-Chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4...)
Affinity DataEC50:  68nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281739(US10023528, Example 25 | US10259776, Example 25)
Affinity DataEC50:  220nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281740(US10023528, Example 27 | US10259776, Example 27)
Affinity DataEC50:  68nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281741(3-(4-Chloro-3-{[(3R)-2-chlorophenyl)-4,4,4-trifluo...)
Affinity DataEC50:  640nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281742((+)-3-(4-Chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4...)
Affinity DataEC50:  11nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281743(US10023528, Example 35 | US10259776, Example 35)
Affinity DataEC50:  11nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent